Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $598.00 Price Target at Bank of America

Key Points

• Bank of America raised its price target on Vertex to $598 from $571 and kept a "buy" rating, implying roughly an 18.7% upside from the recent share price.
• Positive interim results from the RAINIER Phase‑3 trial for povetacicept prompted multiple analyst upgrades and higher targets (e.g., HC Wainwright $641, Oppenheimer $600, Jefferies initiated buy), increasing Street confidence in a potential new kidney franchise.
• Shares jumped to $503.90 on the news; Vertex posted a slight EPS miss ($5.03 vs. $5.05) with revenue up 9.5%, and insiders have sold about 91,156 shares (~$42.8M) in the past 90 days.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price target lifted by equities researchers at Bank of America from $571.00 to $598.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the pharmaceutical company's stock. Bank of America's price target would suggest a potential upside of 18.68% from the stock's current price.

A number of other research firms have also issued reports on VRTX. Morgan Stanley reiterated an "overweight" rating and issued a $570.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. HC Wainwright raised their price target on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a "buy" rating in a research report on Tuesday. Oppenheimer lifted their price objective on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an "outperform" rating in a research note on Tuesday. Sanford C. Bernstein reissued an "outperform" rating and set a $577.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Finally, Royal Bank Of Canada decreased their target price on Vertex Pharmaceuticals from $546.00 to $541.00 and set an "outperform" rating for the company in a research note on Friday, February 13th. Twenty-three equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $550.59.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX traded up $43.03 during mid-day trading on Tuesday, reaching $503.90. 1,415,798 shares of the company's stock traded hands, compared to its average volume of 1,467,100. The business's 50-day moving average price is $467.50 and its 200-day moving average price is $435.79. The stock has a market capitalization of $128.00 billion, a P/E ratio of 32.97 and a beta of 0.31. Vertex Pharmaceuticals has a 12 month low of $362.50 and a 12 month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the previous year, the firm earned $3.98 earnings per share. The business's revenue was up 9.5% compared to the same quarter last year. Equities research analysts anticipate that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 4,910 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the completion of the transaction, the executive vice president directly owned 17,559 shares of the company's stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 58,613 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $468.83, for a total value of $27,479,532.79. Following the completion of the sale, the executive vice president directly owned 58,934 shares of the company's stock, valued at $27,630,027.22. This trade represents a 49.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 91,156 shares of company stock worth $42,845,497 over the last ninety days. Corporate insiders own 0.20% of the company's stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Large investors have recently modified their holdings of the business. Corient Private Wealth LLC boosted its holdings in shares of Vertex Pharmaceuticals by 0.8% in the fourth quarter. Corient Private Wealth LLC now owns 102,570 shares of the pharmaceutical company's stock valued at $46,510,000 after buying an additional 839 shares during the period. Mengis Capital Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $227,000. Rehmann Capital Advisory Group lifted its position in Vertex Pharmaceuticals by 3.3% in the 4th quarter. Rehmann Capital Advisory Group now owns 1,937 shares of the pharmaceutical company's stock valued at $879,000 after acquiring an additional 61 shares in the last quarter. SHP Wealth Management bought a new stake in Vertex Pharmaceuticals in the 4th quarter valued at $220,000. Finally, S Harris Financial Group LLC acquired a new position in Vertex Pharmaceuticals in the 4th quarter worth $209,000. 90.96% of the stock is currently owned by institutional investors.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Povetacicept RAINIER interim analysis met primary and all secondary endpoints, showing meaningful benefit in IgA nephropathy — a potential new commercial franchise that could diversify Vertex’s revenue stream. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: Major analysts raised targets or initiated coverage after the results: Oppenheimer to $600 (Outperform), Jefferies initiated Buy at $580, HC Wainwright raised target to $641, and BMO/William Blair reaffirmed bullish views — signaling increased street confidence in upside from povetacicept and longer-term cash flows. Analyst Coverage & Price Target Moves
• Neutral Sentiment: News and market commentary noted Vertex as a premarket leader and discussed valuation after the move; these pieces provide context for momentum but don’t add new clinical or commercial data. S&P 500 Futures Steady; Vertex Leads
• Neutral Sentiment: Coverage discussing whether the stock remains fairly valued after recent moves may temper near-term upside if investors reassess multiples versus delivery timelines for a new kidney franchise. Is Vertex Still Fairly Priced?
• Negative Sentiment: Recent quarterly results showed only a tiny EPS miss (Feb quarter: $5.03 vs. $5.05 expected) — a reminder that CF franchise growth and near-term financials still matter while new-kidney commercialization timelines, regulatory reviews and competitive dynamics (other IgAN programs) present execution risk.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.